The antibody paradigm: Present and future development as a scaffold for biopharmaceutical drugs

Biotechnology and Genetic Engineering Reviews

Volumn 26, Issue 1, 2009, Pages 1-42

  Jefferis, Roy ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OLIGOSACCHARIDES; SCAFFOLDS (BIOLOGY); STABILITY;

AMINO ACID RESIDUES; BIOPHARMACEUTICAL DRUGS; FUNCTIONAL DIVERSITY; HUMAN ANTIBODIES; HUMORAL IMMUNE RESPONSE; STRUCTURAL DIVERSITY; STRUCTURAL STABILITIES; STRUCTURAL UNIT; STRUCTURAL VARIATIONS; STRUCTURAL-FUNCTIONAL;

ANTIBODIES;

BINDING PROTEIN; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1Q; FC GAMMA RECEPTOR IA; FC GAMMA RECEPTOR IIIA; FC GAMMA RECEPTOR IIIB; FC RECEPTOR; FCRN RECEPTOR; FUCOSE; IGG BINDING PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MANNAN BINDING LECTIN; MANNOSE RECEPTOR; MONOCLONAL ANTIBODY; N ACETYLGLUCOSAMINE; RECOMBINANT ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AMINO TERMINAL SEQUENCE; ANTIBODY ENGINEERING; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; BINDING SITE; CARBOXY TERMINAL SEQUENCE; COMPLEMENT ACTIVATION; COMPLEMENT FIXATION; DNA POLYMORPHISM; DRUG HALF LIFE; DRUG MECHANISM; GLYCOSYLATION; HUMAN; IMMUNOGENICITY; IMMUNOGLOBULIN STRUCTURE; IN VITRO SELECTION; IN VIVO STUDY; INNATE IMMUNITY; INSECT CELL; MOLECULAR INTERACTION; MOLECULAR MECHANICS; MOLECULAR RECOGNITION; MOLECULAR STABILITY; NONHODGKIN LYMPHOMA; NONHUMAN; OUTBRED STRAIN; PLANT; PROKARYOTE; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN GLYCOSYLATION; PROTEIN QUATERNARY STRUCTURE; REVIEW; SIALYLATION; SIGNAL TRANSDUCTION; TRANSCYTOSIS; YEAST;

EID: 77749340045     PISSN: 02648725     EISSN: 20465556     Source Type: Journal    
DOI: 10.5661/bger-26-1     Document Type: Article

References (196)

1. Aalberse, R.C, and Schuurman, J., 2002. IgG4 breaking the rules. Immunology, 105:9–19.
2. Aase, A., and Michaelsen, T.E., 1994. Opsonophagocytic activity induced by chimeric antibodies of the four human IgG subclasses with or without help from complement. Scandanavian Journal of Immunology, 39:581
3. Alavi, A., and Axford, J.S., 2006. The pivotal nature of sugars in normal physiology and disease. Wiener Medizinische Wochenschrift, 156:19–33.
4. Alavi, A, and Axford, J.S., 2008. Glyco-biomarkers:potential determinants of cellular physiology and pathology. Disease Markers, 25:193–205.
5. Andersen, D.C., and Reilly, D.E., 2004. Production technologies for monoclonal antibodies and their fragments. Current Opinion in Biotechnology, 15:456–62.
6. Anolik, J.H., Campbell, D., Felgar, R.E., 2003. The relationship of Fc?RIIIa genotype to degree of B cell depletion by Rituximab in the treatment of systemic lupus erythematosus. Arthritis and Rheumatism, 48:455–59.
7. Anthony, R.M., Wermeling, F., Karlsson, M.C., 2008. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proceedings of the National Academy of Science USA, 105:19571–8.
8. Armour, K.L., Atherton, A., Williamson, L.M., 2002. The contrasting IgG-binding interactions of human and herpes simplex virus Fc receptors. Biochemical Society Transactions, 30:495–500.
9. Arnold, J.N., Wormald, M.R., Suter, D.M., 2005a. Human serum IgM glycosylation:identification of glycoforms that can bind to mannan-binding lectin. Journal of Biological Chemistry, 280:29080–87.
10. Arnold, J.N., Dwek, R.A., Rudd, P.M., 2005b. Mannan binding lectin and its interaction with immunoglobulins in health and in disease. Immunology Letters, 106:103–10.
11. Atalay, R., Zimmermann, A., Wagner, M., 2002. Identification and expression of human cytomegalovirus transcription units coding for two distinct Fcgamma receptor homologs. Journal of Virology, 76:8596–08.
12. Bajtay, Z., Csomor, E., Sandor, N., 2006. Expression and role of Fc- and complement-receptors on human dendritic cells. Immunology Letters, 104:46–52.
13. Bitonti, A.J., and Dumont, J.A., 2006. Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Advances in Drug Delivery Reviews, 58:1106–18.
14. Boyd, P.N., Lines, A.C., and Patel, A.K., 1995. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Molecular Immunology, 32:1311?1318
15. Brambell, F.W.R., Hemmings, W.A., and Morris, I.G., 1964. A theoretical model of gammaglobulin catabolism. Nature, 203:1352–1355.
16. Brekke, O.H., Michaelsen, T.E., and Sandlie, I., 1995. The structural requirements for complement activation by IgG:does it hinge on the hinge?. Immunology Today, 16:85–90.
17. Burton, DR., 1985. Immunoglobulin G - functional sites. Molecular Immunology, 22:161–206.
18. Burton, D.R., and Woof, J.M., 1992. Human antibody effector function. Advances in Immunology, 51:1–84.
19. Cambi, A., and Figdor, C.G., 2003. Levels of complexity in pathogen recognition by C-type lectins Curent. Opinion in Cell Biology, 15:539–46.
20. Campbell, M.P., Royle, L., Radcliffe, C.M., 2008. Glycobase and autoGU:Tools for HPLC based glycan analysis. Bioinformatics, 24:1214–6.
21. Carrasco, B., Garcia de la Torre, J., Davis, K.G., 2001. Crystallohydrodynamics for solving the hydration problem for multi-domain proteins:open physiological conformations for human IgG. Biophysical Chemistry, 93:181–96.
22. Carroll, M.C., 2004. The complement system in regulation of adaptive immunity. Nature Immunology, 5:981–6.
23. Carter, P., Presta, L., Gorman, C.M., 1992. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proceedings of the National Academy of Science USA, 89:4285–89.
24. Carter, P.J., 2006. Potent antibody therapeutics by design. Nature Reviews:Immunology, 6:343–357.
25. Cartron, G., Dacheux, L., Salles, G., 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc?RIIIa gene. Blood, 99:754–758.
26. Chung, C.H., Mirakhur, B., Chan, E., 2008. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. New England Journal of Medicine, 58:1109–17.
27. Corper, A.L., Sohi, M.K., Bonagura, V.R., 1997. Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nature Structural Biology, 4:374–81.
28. Cox, K.M., Sterling, J.D., Regan, J.T., 2006. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nature Biotechnology, 24:1591–97.
29. Coxon, P.Y., Rane, M.J., Powell, D.W., 2000. Differential mitogen-activated protein kinase stimulation by Fc gamma receptor IIa and Fc gamma receptor IIIb determines the activation phenotype of human neutrophils. Journal of Immunology, 164:6530–37.
30. Cremata, J.A, Sorell, L., and Montesino, R., 2003. Hypogalactosylation of serum IgG in patients with coeliac disease. Clinical and Experimental Immunology, 133:422–29.
31. Crispin, M., Stuart, D.I., and Jones, E.Y., 2007. Building meaningful models of glycoproteins. Nature Structural & Molecular Biology, 14:354
32. Dasgupta, S., Navarrete, A. M., Bayry, J., 2007. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Proceedings of the National Academy of Sciences USA, 104:8965–70.
33. Davies, J., Jiang, L., Labarre, M.J., 2001. Expression of GTIII in a recombinant anti-CD20 CHO production cell line:Expression of antibodies of altered glycoforms leads to an increase in ADCC thro' higher affinity for FcRIII. Biotechnology and Bioengineering, 74:288–94.
34. Deisenhoffer, J., 1981. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-Å resolution. Biochemistry, 20:2361–70.
35. Derrick, J.P., and Wigley, D.B., 1994. The third IgG-binding domain from streptococcal protein G. An analysis by X-ray crystallography of the structure alone and in a complex with Fab. Journal of Molecular Biology, 243:906–18.
36. Dong, X., Storkus, W.J., and Salter, R.D., 1999. Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells. Journal of Immunology, 163:5427–34.
37. Drescher, B., Witte, T., and Schmitt, R.E., 2003. Glycosylation of Fc?RIII in N163 as mechanism of regulating receptor affinity. Immunology, 110:335–40.
38. Dubel, S., 2007. Recombinant therapeutic antibodies. Applied Microbiology and Biotechnology, 74:723–9.
39. Duncan, A.R., and Winter, G., 1988. The binding site for C1q on IgG. Nature, 332:738–40.
40. Duquerroy, S., Stura, E.A., Bressanelli, S., 2007. Crystal structure of a human autoimmune complex between IgM rheumatoid factor RF61 and IgG1 Fc reveals a novel epitope and evidence for affinity maturation. Journal of Molecular Biology, 368:1321–31.
41. Desjarlais, J.R., Lazar, G., Zhukovsky, E.A., 2007. Optimizing engagement of the immune system by anti-tumor antibodies:an engineer's perspective. Drug Discovery Today, 12:898–910.
42. Edberg, J.C., and Kimberly, R.P., 1997. Cell type-specific glycoforms of Fc gamma RIIIa (CD16):differential ligand binding. Journal of Immunology, 158:3849–57.
43. Edwards, S.W., Watson, F., and Gasmi, L., 1997. Activation of human neutrophils by soluble immune complexes:role of Fc gamma RII and Fc gamma RIIIb in stimulation of the respiratory burst and elevation of intracellular Ca2+. Annals of the New York Academy of Sciences, 832:341–57.
44. Famm, K., and Winter, G., 2006. Engineering aggregation-resistant proteins by directed evolution. Protein Engineering Design and Selection, 19:479–81.
45. Farooq, M., Takahashi, N., Arrol, H., 1997. Glycosylation of polyclonal and paraprotein IgG in multiple myeloma. Glycoconjugate Journal, 14:489–92.
46. Ferrara, C., Brunker, P., Moser, S., 2006a. Modulation of therapeutic antibody effector functions by glycosylation engineering:influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnology Bioengineering, 93:851–61.
47. Ferrara, C., Stuart, F., Sondermann, P., 2006b. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to nonfucosylated IgG glycoforms. Journal of Biological Chemistry, 281:5032–36.
48. Fitchette, A.C., Dinh, O.T., Faye, L., 2007. Plant proteomics and glycosylation. Methods in Molecular Biology, 355:317–42.
49. Gardy, J.L., Lynn, D.J., Brinkman, F.S., 2009. Hancock RE. Enabling a systems biology approach to immunology:focus on innate immunity. Trends in Immunology, May 8. (Epub ahead of print)
50. Garred, P., Madsen, H.O., Marquart, H., 2000. Two edged role of mannose binding lectin in rheumatoid arthritis:a cross sectional study. Journal of Rheumatology, 2 (7):26–34.
51. Gazi, U., and Martinez-Pomares, L., 2009. Influence of the mannose receptor in host immune responses. Immunobiology, Jan 20. (Epub ahead of print)
52. Georgiou, G., and Segatori, L., 2005. Preparative expression of secreted proteins in bacteria:status report and future prospects. Current Opinion in Biotechnology, 16:538–45.
53. Ghetie, V., and Ward, E.S., 2002. Transcytosis and catabolism of antibody. Immunology Research, 25:97–113.
54. Girardi, E., Holdom, M.D., Davies, A. M., 2009. The crystal structure of rabbit IgG-Fc. Biochemical Journal, 417:77–83.
55. Go, M.F., Schrohenloher, R.E., and Tomana, M., 1994. Deficient galactosylation of serum IgG in inflammatory bowel disease:correlation with disease activity. Journal of Clinical Gastroenterology, 18:86–87.
56. Graille, M., Stura, E.A., Corper, A.L., 2000. Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody:structural basis for recognition of B-cell receptors and superantigen activity. Proceedings of the National Academy of Science USA, 97:5399–404.
57. Groenink, J., Spijker, J., van den Herik-Oudijk, I.E., 1996. On the interaction between agalactosyl IgG and Fc gamma receptors. European Journal of Immunology, 26:1404–7.
58. Guddat, L.W., Herron, J.N., and Edmundson, A.B., 1993. Three-dimensional structure of a human immunoglobulin with a hinge deletion. Proceedings of the National Academy of Science USA, 90:4271–75.
59. Hamilton, S.R., Davidson, R.C., Sethuramann, N., 2006. Humanization of yeast to produce complex terminally sialylated glycoproteins. Science, 313:1441–3.
60. Harris, L.J., 1997. Refined structure of an intact IgG2a monoclonal antibody. Biochemistry, 36:1581–97.
61. Hill, D.R., Aumiller, J.J., Shi, X., 2006. Isolation and analysis of a baculovirus vector that supports recombinant glycoprotein sialylation by SfSWT-1 cells cultured in serum-free medium. Biotechnology and Bioengineering, 95:37–47.
62. Hinton, P.R., Xiong, J.M., Johlfs, M.G., 2006. An engineered human IgG1 antibody with longer serum half-life. Journal of Immunology, 176:346–56.
63. Holgate, R.G., and Baker, M.P., 2009. Circumventing immunogenicity in the development of therapeutic antibodies. IDrugs, 12:233–7.
64. Holland, M., Takada, K., Okumoto, T., 2002. Hypogalactosylation of serum IgG in patients with ANCA-associated systemic vasculitis. Clinical and Experimental Immunology, 29:183–190.
65. Holland, M., Yagi, H., Takahashi, N., 2006. Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA associated systemic vasculitis. Biochimica et Biophysica Acta, 1760:669–77.
66. Huang, L., Biolsi, S., Bales, K.R., 2006. Impact of variable domain glycosylation on antibody clearance:An LC/MS characterization. Analytical Biochemistry, 349:197–207.
67. Jefferis, R., Steinitz, M., and Nik Jaffar, M.I.B., 1984. VIII. A monoclonal rheumatoid factor having specificity for a discontinuous epitope determined by Histidine/Arginine interchange at residue 435 of immunoglobulin G. Immunology Letters, 7:191–94.
68. Jefferis, R., Lund, J., Mizutani, H., 1990. Comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. Biochemical Journal, 268:529–37.
69. Jefferis, R., Lund, J., and Pound, J.D., 1998. IgG-Fc mediated effector functions:molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunological Reviews, 163:59–76.
70. Jefferis, R., 2007. Antibody therapeutics:isotype and glycoform selection. Expert Opinion on Biological Therapeutics, 7:1401–13.
71. Jefferis, R., 2009a. Glycosylation as a strategy to improve antibody-based therapeutics. Nature Reviews:Drug Discovery, 8:226–34.
72. Jefferis, R., and Lefranc, M-P., 2009b. Human immunoglobulin allotypes possible implications for immunogenicity mAb In press
73. Jones, A.J., Papac, D.I., Chin, E.H., 2007. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology, 17:529–40.
74. Jostok, T., 2004. Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries. Journal of Immunological Methods, 289:65–80.
75. Kabelitz, D., and Medzhitov, R., 2007. Innate immunity-cross-talk with adaptive immunity through pattern recognition receptors and cytokines. Current Opinion in Immunology, 19:1–3.
76. Kaneko, Y., Nimmerjahn, F., and Ravetch, J., 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science, 313:670–3.
77. Kaprivova, A., Stemmer, C., Altmann, F., 2004. Targeted knockouts of Physcomitrella lacking plant-specific immunogenic N-glycans. Plant Biotechnology Journal, 2:517–23.
78. Keskin, O., 2007. Binding induced conformational changes of proteins correlate with their intrinsic fluctuations:a case study of antibodies. BMC Structural Biology, 7:31
79. Koene, H.R., Kleijer, M., Algra, J., 1997. Fc?RIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc?RIIIa, independently of the Fc? RIIIa-48L/R/H phenotype. Blood, 90:1109–14.
80. Keck, R., Nayak, N., Lerner, L., 2008. Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content. Biologicals, 36:49–60.
81. Kibe, T., Fujimoto, S., and Ishida, C., 1996. Glycosylation and placental transport of immunoglobulin G. Journal of Clinical Biochemistry and Nutrition, 21:57–63.
82. Kohler, G., and Milstein, C., 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256:495–97.
83. Koki Makabe, K., Nakanishi1, T., Tsumoto, K., 2008. Thermodynamic consequences of Mutations in Vernier Zone Residues of a Humanized Anti-human Epidermal Growth Factor Receptor Murine Antibody, 528. Journal of Biological Chemistry, 283:1156–66.
84. Krapp, S., Mimura, Y., Jefferis, R., 2003. Structural analysis of human IgG glycoforms reveals a correlation between oligosaccharide content, structural integrity and Fc?-receptor affinity. Journal of Molecular Biology, 325:979–89.
85. Kumpel, B.M., Wang, Y., Griffiths, H.L., 1995. The biological activity of human monoclonal IgG anti-D is reduced by beta-galactosidase treatment. Human Antibodies and Hybridomas, 6:82–8.
86. Kumpel, B.M., 2007. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin:more questions than answers. Vox Sang, 93:99–111.
87. Langdon, R.H., Cuccui, J., and Wren, B.W., 2009. N-linked glycosylation in bacteria:an unexpected application. Future Microbiology, 4:401–12.
88. LiÉnard, D., Sourrouille, C., Gomord, V., 2007. Pharming and transgenic plants. Biotechnology Annual Reviews, 13:115–47.
89. Lifely, M.R., Hale, G., and Boyse, S., 1995. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology, 5:813–22.
90. Lim, A., Reed-Bogan, A., and Harmon, B.J., 2008. Glycosylation profiling of a therapeutic recombinant monoclonal antibody with two N-linked glycosylation sites using liquid chromatography coupled to a hybrid quadrupole time-of-flight mass spectrometer. Analytical Biochemistry, 375:163–72.
91. Lin, T.S., Flinn, I.W., Modali, R., 2005. FCGR3A and FCGR2A polymorphisms may not correlate with response to Alemtuzumab in chronic lymphocytic leukemia. Blood, 105:289–91.
92. Lonberg, N., 2008. Fully human antibodies from transgenic mouse and phage display platforms. Current Opinion in Immunology, 20:450–9.
93. Lu, Y., Harding, S.E., Michaelsen, T.E., 2007. Solution conformation of wild-type and mutant IgG3 and IgG4 immunoglobulins using crystallo-hydrodynamics:possible implications for complement activation. Biophysical Journal, 93:3733–44.
94. Lucisano Valim, Y.M., and Lachmann, P.J., 1991. The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes:a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clinical and Experimental Immunology, 84:1–8.
95. Lubinski, J., Nagashunumugan, T., and Friedman, H.M., 1998. Viral interference with antibody and complement. Seminars in Cellular Development and Biology, 9:329–337.
96. Lund, J., Winter, G., Jones, P.T., 1991. Human Fc?RI and Fc?RII interact with distinct but overlapping sites on human IgG. Journal of Immunology, 147:2657–62.
97. Lund, J., Tanaka, T., Takahashi, N., 1990. A protein structural change in aglycosylated IgG3 correlates with loss of huFc gamma R1 and huFc gamma R111 binding and/or activation. Molecular Immunology, 27:1145–53.
98. Lund, J., Takahashi, N., Pound, J., 1996. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc?RI and influence the synthesis of its oligosaccharide chains. Journal of Immunology, 157:4963–69.
99. Louis, E.L., Ghoul, Z., Vermeire, S., 2004. Association between polymorphism in IgG Fc?IIIa coding gene and biological response to Infliximab in Crohn's disease. Alimentary Pharmacology and Therapeutics, 19:511–19.
100. Macor, P., and Tedesco, F., 2007. Complement as effector system in cancer immunotherapy. Immunology Letters, 111:6–13.
101. Maenaka, K., van der Merwe, P.A., Stuart, D.I., 2001. The human low affinity Fcgamma receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties. Journal of Biological Chemistry, 276:44898–904.
102. Magdelaine-Beuzelin, C., Goodall, M., Jefferis, R., 2009. IgG1 heavy chain-coding gene polymorphism, marker of G1m allotypes, and development of antibodies-to-Infliximab. Pharmacogenetics and Genomics, 19:383–7.
103. Malhotra, R., Wormald, M.R., Rudd, P.M., 1995. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannosebinding protein. Nature Medicine, 1:237–43.
104. Makabe, K., 2008. Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528. Journal of Biological Chemistry, 283:1156–66.
105. Marquart, M., Deisenhofer, J., Huber, R., 1980. Crystallographic refinement and atomic models of the intact immunoglobulin molecule Kol and its antigen-binding fragment at 3.0 Å and 1.0 Å resolution. Journal of Molecular Biology, 141:369–91.
106. Masuda, K., Yamaguchi, Y., Kato, K., 2000. Pairing of oligosaccharides in the Fc region of immunoglobulin G. FEBS Letters, 473:349–57.
107. Masuda, K., Kubato, T., Kaneko, E., 2007. Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Molecular Immunology, 44:3122–31.
108. Matsumiya, S., Yamaguchi, Y., Saito, J., 2007. Structural Comparison of Fucosylated and Nonfucosylated Fc Fragments of Human Immunoglobulin G1. Journal of Molecular Biology, 368:767–79.
109. Michaelsen, TE, Brekke, OH, Aase, A., 1994. One disulfide bond in front of the second heavy chain constant region is necessary and sufficient for effector functions of human IgG3 without a genetic hinge. Proceedings of the National Academy of Science USA, 91:9243–47.
110. Michaelsen, T.E., Garred, P., and Aase, A., 1991. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. European Journal of Immunology, 21:11–6.
111. Miescher, S., Spycher, M.O., Amstutz, H., 2004. A single recombinant anti-RhD IgG prevents RhD immunization:association of RhD-positive red blood cell clearance rate with polymorphisms in the Fc?RIIA and Fc?IIIA genes. Blood, 103:4028–35.
112. Mimura, Y., Ashton, P.R., Takahashi, N., 2007. Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry. Journal of Immunological Methods, 326:116–26.
113. Mimura, Y., Church, S., Ghirlando, R., 2000. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc:properties of a series of truncated glycoforms. Molecular Immunology, 37:697–706.
114. Mimura, Y., Ashton, P.R., Takahashi, N., 2007. Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry. J Immunol Methods, 326:116–26.
115. Mimura, Y., Sondermann, P., Ghirlando, R., 2001. The role of oligosaccharide residues of IgG1-Fc in Fc?IIb binding. Journal of Biological Chemistry, 276:45539–47.
116. H2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc?RI and Fc?RII binding. Immunology, 86:319–24.
117. Moutel, S., and Perez, F., 2008. Antibodies-Europe. Engineering the next generation of antibodies. Biotechnology Journal, 3:298–300.
118. Namboodiri, A.M., Budkowska, A., Niertert, P.J., 2007. Fc gamma receptor-like hepatitis C virus core protein binds differentially to IgG of discordant Fc (GM) genotypes. Molecular Immunology, 44:3805–08.
119. Natsume, A., Wakitani, M., Yamane-Ohnuki, N., 2005. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region. Journal of Immunological Methods, 306:93–103.
120. Natsume, A., Wakitani, M., Yamane-Ohnuki, N., 2006. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region. Journal of Biochemistry, 140:359–368.
121. Natsume, A., In, M., Takamura, H., 2008. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Research, 68:3863–72.
122. Nezlin, R., and Ghetie, V., 2004. Interactions of immunoglobulins outside the antigencombining site. Advances in Immunology, 82:155–215.
123. Nimmerjahn, F., and Ravetch, J., 2007. Fc-receptors as regulators of immunity. Advances in Immunology, 96:179–204.
124. Nimmerjahn, F., and Ravetch, J., 2008. Fcgamma receptors as regulators of immune responses. Nature Reviews in Immunology, 8:34–47.
125. Nitsche-Schmitz, D.P., Johansson, H.M., Sastalla, I., 2007. Group G streptococcal IgG binding molecules FOG and protein G have different impacts on opsonization by C1q. Journal of Biological Chemistry, 282:17530–36.
126. Niwa, R., Natsume, A., Uehara, A., 2005. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. Journal of Immunological Methods, 306:151–60.
127. Novak, J., Tomana, M., Shah, G.R., 2005. Heterogeneity of IgG glycosylation in adult periodontal disease. Journal of Dental Research, 84:897–901.
128. Okazaki, A., Shoji-Hosaka, E., and Nakamura, K., 2004. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. Journal of Molecular Biology, 336:1239–49.
129. Olsen, JK., Santos, R.A., and Grose, C., 1998. Varicella-zoster virus glycoprotein gE:endocytosis and trafficking of the Fc receptor. Journal of Infectious Disease, 178 (1):S2–6.
130. Padlan, E. A., 1990. “ Fc receptors and the action of antibodies ”. Edited by:Metzger H, H., 12–30. Washington D.C:American Society for Microbiology.
131. Padlan, E.A., 1996. X-ray crystallography of antibodies. Advances in Protein Chemistry, 49:57–133.
132. Parekh, R.B., Dwek, R.A., and Sutton, B.J., 1985. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature, 316:452–57.
133. Pascoe, D.E., Arnott, D., Papoutsakis, E.T., 2007. Proteome analysis of antibody-producing CHO cell lines with different metabolic profiles. Biotechnology and Bioengineering, 98:391–410.
134. Peipp, M., Lammerts van Bueren, J.J., and Schneider-Merck, T., 2008. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood, 112:2390–9.
135. Podack, E.R., Deyev, V., and Shiratsuchi, M., 2007. Pore formers of the immune system. Advances in Experimental Medicine and Biology, 598:325–41.
136. Potgieter, T.I., Cukan, M., and Drummond, J.E., 2009. Production of monoclonal antibodies by glycoengineered Pichia pastoris. Journal of Biotechnology, 139:318–25.
137. Presta, L., 2008. Molecular engineering and design of therapeutic antibodies. Current Opinion in Immunology, 20:460–70.
138. H1 Constant Region Domain Modulate Antigen Binding Affinity of Antibodies?. Journal of Clinical Investigation, 98:2235–43.
139. Qian, J., Liu, T., Yang, L., 2007. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Analytical Biochemistry, 364:8–18.
140. Radaev, S., Motyka, S., Fridman, W.H., 2001. The structure of human type Fc?III receptor in complex with Fc. Journal of Biological Chemistry, 276:16469–77.
141. Radaev, S., and Sun, P., 2002. Recognition of immunoglobulins by Fc gamma receptors. Molecular Immunology, 38:1073–83.
142. Radaev, S., and Sun, P.D., 2001. Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors. Journal of Biological Chemistry, 276:16478–83.
143. Radstake, T.R., Svenson, M., and Eijsbouts, A.M., 2008. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Annals of Rheumatic Diseases, 2008 Nov 19. (Epub ahead of print)
144. Raju, T.S., and Scallon, B., 2007. Fc glycans terminated with N-acetylglucosamine residues increase antibody resistance to papain. Biotechnology Progress, 23:964–71.
145. Raju, T.S., and Scallon, B., 2006. Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain. Biochemical Biophysical Research Communications, 341:797–803.
146. Redpath, S., Michaelsen, T.E., Sandlie, I., 1998. The influence of the hinge region length in binding of human IgG to human Fcgamma receptors. Human Immunology, 59:720–7.
147. Reichert, J.M., and Valge-Archer, V.E., 2007. Development trends for monoclonal antibody cancer therapeutics. Nature Reviews:Drug Discovery, 6:349–56.
148. Rhodes, D.A., and Trowsdale, J., 2007. TRIM21 is a trimeric protein that binds IgG Fc via the B30.2 domain. Molecular Immunology, 44:2406–14.
149. Rodriguez, M.E., van der Pol, W-L., and Sanders, L.A.M., 1999. Crucial role of Fc RIIa (CD32) in assessment of functional anti-Streptococcus pneumoniae antibody activity in human sera. Journal of Infectious Diseases, 179:423–33.
150. Roopenian, D.C., and Akilesh, S., 2007. FcRn:the neonatal Fc receptor comes of age. Nature Reviews:Immunology, 7:715–25.
151. Roux, K.H., Strelets, L., and Michaelsen, T.E., 1997. Flexibility of human IgG. subclasses. Journal of Immunology, 159:3372–82.
152. Routier, F.H., Hounsell, E.F., Rudd, P.M., 1998. Quantitation of human IgG glycoforms isolated from rheumatoid sera:a critical evaluation of chromatographic methods. Journal of Immunological Methods, 213:113–30.
153. Rudd, P.M., and Dwek, R.A., 1997. Glycosylation:heterogeneity and the 3D structure of proteins. Critical Reviews in Biochemistry and Molecular Biology, 32:1–100.
154. Saevarsdottir, S., Vikingsdottir, T., and Valdimarsson, H., 2004. The potential role of mannan-binding lectin in the clearance of self-components including immune complexes. Scandanavian Journal of Immunology, 60:23–9.
155. Sanguineti, S., CentenoCrowley, J.M., 2007. Specific recognition of a DNA immunogen by its elicited antibody. Journal of Molecular Biology, 370:183–95.
156. Sagawa, T., Oda, M., Morii, H., 2005. Conformational changes in the antibody constant domains upon hapten-binding. Molecular Immunology, 42:9–18.
157. Saphire, E.O., Stanfield, R.L., Crispin, M.D., 2002. Contrasting IgG structures reveal extreme asymmetry and flexibility. Journal of Molecular Biology, 319:9–18.
158. Satoh, M., Iida, S., and Shitara, K., 2006. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opinion on Biological Therapy, 6:1161–73.
159. Sauer-Eriksson, A.E., Kleywegt, G.J., Uhl, M., 1995. Crystal structure of the C2 fragment of streptococcal protein G in complex with the Fc domain of human IgG. Structure, 3:265–278.
160. Scallon, B., Tam, S.H., McCarthy, S.G., 2007. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Molecular Immunology, 44:1524–34.
161. Shibata-Koyama, M., Iida, S., Misaka, H., 2009. Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. Experimental Hematology, 37:309–21.
162. Shields, R.L., Namenuk, A.K., Hong, K., 2001. High resolution mapping of the binding site on human IgG1 for Fc?RI, Fc?RII, Fc?RIII, and FcRn and design of IgG1 variants with improved binding to the Fc?R. Journal of Biological Chemistry, 276:6591–604.
163. Shields, R.L., Lai, J., Keck, R., 2002. Lack of Fucose on Human IgG1 N-Linked oligosaccharide improves binding to human Fc?RIII and Antibody-dependent cellular toxicity. Journal of Biological Chemistry, 277:26733–40.
164. Shinkawa, T, Nakamura, K, Yamane, N. 2003. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. Journal of Biological Chemistry, 278:3466–73.
165. Shoji-Hosaka, E., Kobayashi, Y., Wakitani, Y., 2006. Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides. Journal of Biochemistry (Tokyo), 140:777–83.
166. Siberil, S., Dutertre, C.A., and Fridman, W.H., 2007. The key to optimize therapeutic antibodies?. Critical Reviews in Oncology and Hematology, 62:26–33.
167. Simister, N.E., and Mostov, K.E., 1989. An Fc receptor structurally related to MHC class I antigens. Nature, 337:184–7.
168. Simister, N.E., 2003. Placental transport of immunoglobulin G. Vaccine, 21:3365–69.
169. Sohi, M.K., Corper, A.L., Wan, T., 1996. Crystallization of a complex between the Fab fragment of a human immunoglobulin M (IgM) rheumatoid factor (RF-AN) and the Fc fragment of human IgG4. Immunology, 88:636–41.
170. Sondermann, P., Huber, R., Oosthuizen, V., 2000. The 3.2-A crystal structure of the human IgG1 Fc -Fc?RIII complex. Nature, 406:267–273.
171. Sondermann, P., Kaiser, J., and Jacob, U., 2001. Molecular basis for immune complex recognition:a comparison of Fc-receptor structures. Journal of Molecular Biology, 309:737–49.
172. Sprague, E.R., Martin, W.L., and Bjorkman, P.J., 2004. pH dependence and stoichiometry of binding to the Fc region of IgG by the herpes simplex virus Fc receptor gE-gI. Journal of Biological Chemistry, 279:14184–93.
173. Stanfield, R.L., Zemla, A., Wilson, I.A., 2006. Antibody elbow angles are influenced by their light chain class. Journal of Molecular Biology, 357:1566–74.
174. Suzuki, E., Niwa, R., Saji, S., 2007. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clinical Cancer Research, 13:1875–82.
175. Taylor, M.E., and Drickamer, K., 2003. Structure-function analysis of C-type animal lectins. Methods in Enzymology, 363:3–16.
176. Umana, P., Jean-Mairet, J., Moudry, R., 1999. Engineered glycoforms of an anti-neuroblastoma. IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nature Biotechnology, 17:176–80.
177. Vaccaro, C., Zhou, J., Ober, R.J., 2005. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nature Biotechnology, 23:1283–88.
178. van der Neut Kolfschoten, M., Schuurman, J., Losen, M., 2007. Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange. Science, 317:1554–7.
179. Van Droogenbroeck, B., Cao, J., Stadlmann, J., 2007. Aberrant localization and underglycosylation of highly accumulating single-chain Fv-Fc antibodies in transgenic Arabidopsis seeds. Proceedings of the National Academy of Science USA, 104:1430
180. Voice, J.K., and Lachmann, P.J., 1997. Neutrophil Fc gamma and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes. European Journal of Immunology, 27:2514–23.
181. Walker, M.R., Lund, J., Thompson, K.M., 1989. Aglycosylation of human IgG1 and Igg3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. Biochemical Journal, 259:347–53.
182. Walsh, G., and Jefferis, R., 2006. Post-translational modifications in the context of therapeutic proteins. Nature Biotechnology, 24:1241–52.
183. Wang, S.Y., and Weiner, G., 2008. Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opinion on Biological Therapy, 8:759–68.
184. Warmerdam, P.A.M., van de Winkel, J.G.J., Vlug, A., 1991. A single amino acid in the second IgG like domain of the human Fc? receptor II is critical for human IgG2 binding. Journal of Immunology, 147:1338–43.
185. Webster, A.C., Pankhurst, T., Rinaldi, F., 2006. Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients:a systematic review of randomized trial data. Transplantation, 81:953–65.
186. West, A.P., and Bjorkman, P.J., 2000. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor. Biochemistry, 39:9698–708.
187. Williams, P.J., Arkwright, P.D., and Rudd, P.M., 1995. Short communication:Selective transport of maternal IgG to the foetus. Placenta, 16:749–56.
188. Woof, J.M., Partridge, L.J., Jefferis, R., 1986. Localisation of the monocyte binding region on immunoglobulin G. Molecular Immunology, 23:319–30.
189. Woof, J.M., and Burton, D.R., 2004. Human antibody-Fc receptor interactions illuminated by crystal structures. Nature Reviews:Immunology, 4:89–99.
190. Wormald, M.R., Rudd, P. M., Harvey, D.J., 1997. Variations in oligosaccharideprotein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. Biochemistry, 36:1370–80.
191. Woodnutt, G., Violand, B., and North, M., 2008. Advances in protein therapeutics. Current Opinion in Drug Discovery and Development, 11 (6):754–61.
192. Wuhrer, M., Porcelijn, L., Kapur, R., 2009. Regulated glycosylation patterns of IgG during alloimmune responses against human platelet antigens. Journal of Proteome Research, 8:450–6.
193. Yamada, E., Tsukamoto, Y., Sasaki, R., 1997. Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum. Glycoconjugate Journal, 14:401–5.
194. Yamaguchi, Y., Kato, K., Shindo, M., 1990. Dynamics of the carbohydrate chains attached to the Fc portion of immunoglobulin G as studied by NMR spectroscopy assisted by selective 13C labeling of the glycans. Journal of Biomolecular NMR, 12:385–94.
195. Yamaguchi, Y., Nishimura, M., Nagano, M., 2006. Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. Biochimica et Biophysica Acta, 1760:693–700.
196. Youings, A., Chang, S.C., Dwek, R.A., 1996. Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients. Biochemical Journal, 314:621–30.